Pharmaceutical Commerce - June 2024 Issue (PDF)

James D. Chambers, PhD, MPharm, MSc, professor of medicine at the Tufts Medical Center Institute for Clinical Research and Health Policy Studies, dives into why biosimilars contribute to a reduction in cost and increase in patient access, while highlighting challenges to adoption.

Donald Prentiss discusses the value of these pharmacies, especially during shortages.

FDA approves an expanded access program that would offer patients an alternative to Merck’s bladder cancer medication.

Vibhu Tewary offers insight on this market segment, including a behind-the-scenes of what goes into designing a report.

The timing for the potential tax is yet to be determined, as the industry awaits to see the impact it could bring.

The latest news for pharma industry insiders.